Listed as “Pearl Bio”
- First observed:
- 31 Oct 2026
- Investment announced:
- Date not recorded
Pearl Bio develops platforms for biologics and biomaterials.
Pearl Bio combines genome and ribosome engineering to produce biologics with varied chemistries. Its manufacturing platform combines biological and chemical approaches to create template-directed biomaterials with tunable properties.
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Pearl Bio”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.